Actos Pay-For-Delay Class Action Gets The Boot
Takeda and five generic-drug makers escaped a pay-for-delay suit over the diabetes drug Actos when a New York federal judge ruled Tuesday that drug buyers relied on too broad an interpretation...To view the full article, register now.
Already a subscriber? Click here to view full article